Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 2, 2008, Pages 141-151

  Gagne, J J ^a   Maio, V ^a   Rabinowitz, C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Drug drug interactions; Pharmacoepidemiology; Prescriptions; Prevalence

Indexed keywords

AMINOPHYLLINE; CELECOXIB; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; DICLOFENAC; ERGOTAMINE; ERYTHROMYCIN; FENOFIBRATE; FLURBIPROFEN; FLUVOXAMINE; GEMFIBROZIL; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PHENOBARBITAL; PIROXICAM; PRIMIDONE; ROFECOXIB; SULINDAC; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; FEMALE; FOLLOW UP; HUMAN; INFANT; ITALY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESCRIPTION; PREVALENCE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; AMINOPHYLLINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BARBITURATES; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; DRUG INTERACTIONS; DRUG UTILIZATION; FEMALE; FLUVOXAMINE; HUMANS; ITALY; MALE; MIDDLE AGED; OUTPATIENTS; THEOPHYLLINE; WARFARIN;

EID: 40349110843     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00891.x     Document Type: Article

References (81)

1. Hartshorn EA (ed 1973) Handbook of drug interactions. Hamilton, Illinois : Drug Intelligence Publications.
2. Peterson JF, Bates DW (2001) Preventable medication errors: identifying and eliminating serious drug interactions. Journal of the American Pharmacists Association, 41, 159 160.
3. Gurwitz JH, Field TS, Harrold LR et al. (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. Journal of the American Medical Association, 289, 1107 1116.
4. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM (2004) Oral erythromycin and the risk of sudden death from cardiac causes. New England Journal of Medicine, 351, 1089 1096.
5. Knijff-Dutmer EA, Schut GA, van de Laar MA (2003) Concomitant coumarin-NSAID therapy and risk for bleeding. Annals of Pharmacotherapy, 37, 12 16.
6. Zapater P, Reus S, Tello A, Torrus D, Perez-Mateo M, Horga JF (2002) A prospective study of the clarithromycin-digoxin interaction in elderly patients. Journal of Antimicrobial Chemotherapy, 50, 601 606.
7. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. Journal of the American Medical Association, 289, 1652 1658.
8. Liddle BJ (1991) Methotrexate interactions. Clinical and Experimental Dermatology, 16, 311 312.
9. Steuer A, Gumpel JM (1998) Methotrexate and trimethoprim: a fatal interaction. British Journal of Rheumatology, 37, 105 106.
10. Govert JA, Patton S, Fine RL (1992) Pancytopenia from using trimethoprim and methotrexate. Annals of Internal Medicine, 117, 877 878.
11. Flockhart DA, Drici MD, Kerbusch T et al. (2000) Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. Journal of Clinical Psychopharmacology, 20, 317 324.
12. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiology and Drug Safety, 16, 641 651.
13. Jonsson AK, Spigset O, Jacobsson I, Hagg S (2007) Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions. Pharmacoepidemiology and Drug Safety, 16, 309 315.
14. Jinks MJ, Hansten PD, Hirschman JL (1979) Drug interaction exposures in an ambulatory Medicaid population. American Journal of Hospital Pharmacy, 36, 923 927.
15. Solberg LI, Hurley JS, Roberts MH et al. (2004) Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. American Journal of Managed Care, 10, 753 759.
16. Peng CC, Glassman PA, Marks IR, Fowler C, Castiglione B, Good CB (2003) Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. Journal of Managed Care Pharmacy, 9, 513 522.
17. Malone DC, Hutchins DS, Haupert H et al. (2005) Assessment of potential drug-drug interactions with a prescription claims database. American Journal of Health-System Pharmacy, 62, 1983 1991.
18. Cruciol-Souza JM, Thomson JC (2006) Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. Journal of Pharmaceutical Sciences, 9, 427 433.
19. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S (2005) Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Safety, 28, 263 275.
20. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH (2005) Incidence and possible causes of prescribing potentially hazardous/ contraindicated drug combinations in general practice. Drug Safety, 28, 67 80.
21. Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scandinavian Journal of Primary Health Care, 21, 153 158.
22. Bjorkman IK, Fastbom J, Schmidt IK, Bernsten CB, Pharmaceutical Care of the Elderly in Europe Research (PEER) Group (2002) Drug-drug interactions in the elderly. Annals of Pharmacotherapy, 36, 1675 1681.
23. Galatti L, Mazzaglia G, Greco A et al. (2007) Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice. Pharmacoepidemiology and Drug Safety, 16, 422 428.
24. Wun YT, Chan CS, Dickinson JA (2002) Determinants of physicians' attitude towards prescribing. Journal of Clinical Pharmacy and Therapeutics, 27, 57 65.
25. Glassman PA, Simon B, Belperio P, Lanto A (2002) Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Medical Care, 40, 1161 1171.
26. Weideman RA, Bernstein IH, McKinney WP (1999) Pharmacist recognition of potential drug interactions. American Journal of Health-System Pharmacy, 56, 1524 1529.
27. Cavuto NJ, Woosley RL, Sale M (1996) Pharmacies and prevention of potentially fatal drug interactions. Journal of the American Medical Association, 275, 1086 1087.
28. Italian Ministry of Health. I farmaci del servizio sanitario nazionale anno I - N.1/2001 Ministero della Sanità, Istituto Poligrafico e Zecca dello Stato.
29. Louis DZ, Yuen EJ, Maio V et al. (2005) A population-based longitudinal healthcare database in the Emilia-Romagna Region, Italy: a resource for planning and research. Health Policy Newsletter, 18, 6.
30. Abarca J, Malone DC, Armstrong EP et al. (2004) Concordance of severity ratings provided in four drug interaction compendia. Journal of the American Pharmacists Association, 44, 136 141.
31. Fulda TR, Valuck RJ, Zanden JV, Parker S, Byrns PJ (2000) Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Current Therapeutic Research, 61, 540 548.
32. Valuck RJ, Byrns PJ, Fulda TR, Zanden JV, Parker S (2000) Methodology for assessing drug-drug interaction evidence in the peer-reviewed medical literature. Current Therapeutic Research, 61, 553 568.
33. Malone DC, Abarca J, Hansten PD et al. (2004) Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. Journal of the American Pharmacists Association, 44, 142 151.
34. ® system. Greenwood Village, CO : Micromedex.
35. Stoner SC, Lea JW, Dubisar BM, Farrar C (2003) Possible international normalized ratio elevation associated with celecoxib and warfarin in an elderly psychiatric patient. Journal of the American Geriatrics Society, 51, 728 729.
36. Flessner MF, Knight H (1988) Prolongation of prothrombin time and severe gastrointestinal bleeding associated with combined use of warfarin and ketoprofen. Journal of the American Medical Association, 259, 353.
37. Chan TY, Lui SF, Chung SY, Luk S, Critchley JA (1994) Adverse interaction between warfarin and indomethacin. Drug Safety, 10, 267 269.
38. Schulman S, Henriksson K (1989) Interaction of ibuprofen and warfarin on primary haemostasis. British Journal of Rheumatology, 28, 46 49.
39. Ross JR, Beeley L (1979) Sulindac, prothrombin time, and anticoagulants. Lancet, 2, 1075.
40. Linder JD, Monkemuller KE, Davis JV, Wilcox CM (2000) Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. Southern Medical Journal, 93, 930 932.
41. Malhi H, Atac B, Daly AK, Gupta S (2004) Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgraduate Medical Journal, 80, 107 109.
42. Avery GS (1973) Check-list to potential clinically important interactions. Drugs, 5, 187 211.
43. Weser JK, Sellers E (1971) Drug interactions with coumarin anticoagulants. New England Journal of Medicine, 85, 547 558.
44. Udall JA (1975) Clinical implications of warfarin interactions with five sedatives. American Journal of Cardiology, 35, 67 71.
45. Kim KY, Mancano MA (2003) Fenofibrate potentiates warfarin effects. Annals of Pharmacotherapy, 37, 212 215.
46. Ascah KJ, Rock GA, Wells PS (1998) Interaction between fenofibrate and warfarin. Annals of Pharmacotherapy, 32, 765 768.
47. Aldridge MA, Ito MK (2001) Fenofibrate and warfarin interaction. Pharmacotherapy, 21, 886 889.
48. Ahmad S (1990) Gemfibrozil interaction with warfarin sodium (coumadin). Chest, 98, 1041 1042.
49. Rindone JP, Keng HC (1998) Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia. Chest, 114, 641 642.
50. Desmond PV, Mashford ML, Harman PJ, Morphett BJ, Breen KJ, Wang YM (1984) Decreased oral warfarin clearance after ranitidine and cimetidine. Clinical Pharmacology and Therapeutics, 35, 338 341.
51. Silver BA, Bell WR (1979) Cimetidine potentiation of the hypoprothrombinemic effect of warfin. Annals of Internal Medicine, 90, 348 349.
52. Flind AC (1978) Cimetidine and oral anticoagulants. British Medical Journal, 2, 1367.
53. O'Reilly RA (1984) Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Archives of Internal Medicine, 144, 989 991.
54. Kerley B, Ali M (1982) Cimetidine potentiation of warfarin action. Canadian Medical Association Journal, 126, 116.
55. Raoof S, Wollschlager C, Khan FA (1987) Ciprofloxacin increases serum levels of theophylline. American Journal of Medicine, 82, 115 118.
56. Wijnands WJ, Vree TB, van Herwaarden CL (1986) The influence of quinolone derivatives on theophylline clearance. British Journal of Clinical Pharmacology, 22, 677 683.
57. Andrews PA (1998) Interactions with ciprofloxacin and erythromycin leading to aminophylline toxicity. Nephrology Dialysis Transplantation, 13, 1006 1008.
58. Sperber AD (1991) Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety, 6, 460 462.
59. Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C (1988) Dihydroergotamine-erythromycin-induced ergotism. Annals of Internal Medicine, 109, 249.
60. Ng HW, Macfarlane AW, Graham RM, Verbov JL (1987) Near fatal drug interactions with methotrexate given for psoriasis. British Medical Journal (Clinical Research Edition), 295, 752 753.
61. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG (1983) Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clinical Pharmacology and Therapeutics, 34, 810 817.
62. LeBel M, Masson E, Guilbert E et al. (1998) Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. Journal of Clinical Pharmacology, 38, 1042 1050.
63. Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orme ML, Rowe PH (1981) Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs, 21, 46 61.
64. True RJ (1982) Interactions between antibiotics and oral contraceptives. Journal of the American Medical Association, 247, 1408.
65. Szoka PR, Edgren RA (1988) Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertility and Sterility, 49, 31S 38S.
66. Desta Z, Kerbusch T, Flockhart DA (1999) Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clinical Pharmacology and Therapeutics, 65, 10 20.
67. Oberg KC, Bauman JL (1995) QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy, 15, 687 692.
68. ® (pimozide). Sellersville, PA : Gate Pharmaceuticals.
69. Webb DJ, Freestone S, Allen MJ, Muirhead GJ (1999) Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. American Journal of Cardiology, 83, 21C 28C.
70. Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW (2000) Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. Journal of the American College of Cardiology, 36, 25 31.
71. ACT/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology (2006) http://www.whocc.no/atcddd/, accessed October 11.
72. Tobi H, Faber A, van den Berg PB, Drane JW, de Jong-van den Berg LT (2006) Studying co-medication patterns: the impact of definitions. Pharmacoepidemiology and Drug Safety, 16, 405 411.
73. Maio V, Yuen E, Rabinowitz C et al. (2005) Using pharmacy data to identify those with chronic conditions in Emilia Romagna, Italy. Journal of Health Services Research and Policy, 10, 232 238.
74. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE (1995) A chronic disease score with empirically derived weights. Medical Care, 33, 783 795.
75. Maio V, Yuen EJ, Novielli K, Smith KD, Louis DZ (2006) Potentially inappropriate medication prescribing for elderly outpatients in Emilia Romagna, Italy: a population-based cohort study. Drugs and Aging, 23, 915 924.
76. Kotirum S, Chaiyakunapruk N, Jampachaisri K, Wattanasombat S, Rojnuckarin P (2007) Utilization review of concomitant use of potentially interacting drugs in Thai patients using warfarin therapy. Pharmacoepidemiology and Drug Safety, 16, 216 222.
77. Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW (2005) Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiology and Drug Safety, 14, 755 767.
78. Staniscia T, Romano F, Festi D, Bilker WB, Macones GA, Strom BL (2006) Co-dispensing of contraindicated medications in patients using cisapride in Italy. Pharmacoepidemiology and Drug Safety, 15, 469 476.
79. Gau CS, Chang IS, Lin Wu FL et al. (2007) Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan. Pharmacoepidemiology and Drug Safety, 16, 86 95.
80. Minicucci F, Muscas G, Perucca E, Capovilla G, Vigevano F, Tinuper P (2006) Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy. Epilepsia, 47 (Supplement 9 15.
81. Becker ML, Kallewaard M, Caspers PW, Schalekamp T, Stricker BH (2005) Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Safety, 28, 371 378.